# Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

> **NCT00060138** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chugai Pharmaceutical**

## Conditions studied

- Breast Cancer
- Hypercalcemia of Malignancy
- Metastatic Cancer
- Pain

## Interventions

- **BIOLOGICAL:** monoclonal antibody CAL
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00060138
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-09
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060138, "Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00060138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*